SMARCB1 and kidney cancer: While currently available therapies have substantially improved the clinical outcomes of many patients with kidney cancers, these treatments are typically ineffective against highly aggressive SMARCB1-deficient kidney malignancies such as renal medullary carcinoma (RMC)1–4.